A Phase II, Randomized, Open-Label Study to Evaluate the Comparative Safety and Immunogenicity of 1.0 microg Intramuscular (i.m.) and 2.0 microg Subcutaneous (s.c.) Dosing With VAX102 (M2e-Flagellin) in Healthy Adults.

Trial Profile

A Phase II, Randomized, Open-Label Study to Evaluate the Comparative Safety and Immunogenicity of 1.0 microg Intramuscular (i.m.) and 2.0 microg Subcutaneous (s.c.) Dosing With VAX102 (M2e-Flagellin) in Healthy Adults.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2011

At a glance

  • Drugs VAX 102 (Primary)
  • Indications Influenza A virus infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 06 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jun 2009 Official Title added, patient number added as 60, additional lead trial investigator David N Taylor, additional trial location as USA as reported by ClinicalTrials.gov.
    • 18 Jun 2009 Planned end date added as 1 Aug 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top